(E)-8-Hexadecenal

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-8-Hexadecenal
• 英文别名: 8-n-hexadecenoic aldehyde；8-hexadecenal, E；(E)-hexadec-8-enal
• 化学式: C₁₆H₃₀O
• 分子量: 238.414
• InChiKey: CDLTZHMYSOPNNK-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  17
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA
  申请人：Hadwiger Philipp

  公开号：US20120157509A1

  公开（公告）日：2012-06-21

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内细胞的组合物。与单独的靶向配体相比，药代动力学调节剂改善了体内靶向。靶向配体-药代动力学调节剂靶向基团靶向的RNAi多核苷酸可以单独或与共靶向递送聚合物一起在体内给予。
• Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA
  申请人：Arrowhead Madison Inc.

  公开号：US20160102120A1

  公开（公告）日：2016-04-14

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

  本发明涉及用于靶向RNA干扰（RNAi）多核苷酸的组成物，以在体内将其传递至细胞。药代动力学调节剂可提高体内靶向性，相较于仅使用靶向配体。靶向配体-药代动力学调节剂靶向基团靶向RNAi多核苷酸可以单独或与共靶向递送聚合物一起在体内给予。
• Oligonucleotide conjugates
  申请人：Roche Innovation Center Copenhagen A/S

  公开号：US10077443B2

  公开（公告）日：2018-09-18

  The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.

  本发明涉及寡核苷酸治疗领域，尤其涉及使用可裂解的，例如共价连接到共轭物、靶向基团或阻断基团上的磷酸二酯区来增强寡核苷酸的特性，例如提高治疗指数。
• Poly oligomer compound with biocleavable conjugates
  申请人：Hoffmann-LA Roche Inc.

  公开号：US10358643B2

  公开（公告）日：2019-07-23

  The invention relates to the field of oligonucleotide therapeutics, and in particular to poly oligo oligonucleotides conjugates where two or more antisense oligonucleotides are covalently linked by physiologically labile linkers, and to a biocleavable functional group such as a conjugate group.

  本发明涉及寡核苷酸治疗领域，特别是涉及聚寡核苷酸共轭物，其中两个或多个反义寡核苷酸通过生理上易失效的连接体共价连接，并涉及生物可分解的官能团，如共轭基团。
• Manufacture of antisense oligomers and conjugates targeting PCSK9
  申请人：ROCHE INNOVATION CENTER COPENHAGEN A/S

  公开号：US10370668B2

  公开（公告）日：2019-08-06

  The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.

  本发明涉及低聚物化合物及其共轭物，它们能靶向细胞中的前蛋白转化酶 Subtilisin/Kexin 9 型（PCSK9）PCSK9 mRNA，导致 PCSK9 的表达减少。减少 PCSK9 的表达有利于治疗一系列疾病，如高胆固醇血症和相关疾病。